Skip to main content
Podcast: Discussing the Ceregene Clinical Trial Results

Podcast: Discussing the Ceregene Clinical Trial Results

In this podcast, MJFF Contributing Editor Dave Iverson reports on recent disappointing clinical trial results of San Diego-based biotech Ceregene’s trophic factor therapy CERE-120.

For perspective on what the results mean for CERE-120 and trophic factors moving forward, Iverson speaks with William Marks, MD, of the University of California San Francisco Medical Center, and Jamie Eberling, PhD, senior associate director of research programs at MJFF.


And next week, we invite you to learn more about the “Future of Trophic Factors.” Join the conversation on May 1st at noon ET by signing up for our breaking news Webinar with MJFF Chief Scientific Advisor/neurturin co-discoverer Gene Johnson, PhD, MJFF CEO Todd Sherer, PhD and Marks.

Register to participate!

You can also learn more by reading our News in Context report with Johnson and Eberling. 


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.